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EditorialStepping Stones on Solid GroundAs I write this editorial, we are gearing up for the 2010 ISSCR
meeting in San Francisco. This year’s meeting seems set to be
the biggest ever, with around 3500 expected attendees and
108 speakers from 15 countries around the world. Thanks to
generous sponsorship from CIRM, all meeting attendees will
receive a free copy of this issue of Cell Stem Cell with the regis-
tration package. I hope many of you who are attending will also
find time to stop by the Cell Press booth in the exhibit hall and
enter our competition to win a set of Bose headphones. At the
booth, you can also learn about our ‘‘Article of the Future’’
format, our meeting programs, and several other new initiatives.
For Cell Stem Cell specifically, this month sees the debut of
article collections on our website, with the first compilations
providing a ready reference point for our wide range of reviews,
resource articles, and ethics/policy discussions.
For this year’s anniversary issue, our review feature focuses on
a topic that has been the subject of considerable debate: how
best to translate stem cell research into safe and effective ther-
apies. For most of the research presented at the meeting and
in Cell Stem Cell, application to therapy is still a long way off.
For some studies, however, the potential translational benefits
are more readily apparent, and our new ‘‘In Translation’’ articles
will highlight such cases and discuss the steps that still need to
be taken to use the findings for clinical benefit. Despite the time
frame disconnect, funding and regulatory agencies need to be
‘‘ahead of the curve’’ in thinking about approaches for moving
from basic research to development of biological drugs, partic-
ularly given the expense involved. As an illustration of the steps
that need to be taken, two Forum articles discuss approaches in
Europe (Cuende and Izeta, 2010) and in the U.S. (Trounson et al.,
2010). Both pieces highlight the funding gap that exists between
basic research and pharmaceutical drug development, and
efforts by the agencies involved to establish financial ‘‘stepping
stones’’ that will help bridge the divide. They both also mention
that pharmaceutical companies have overall been wary about
diving into the cell-based (or cell-focused) therapy arena.
However, in their article McKernan et al. (2010) argue that oppor-
tunities and interest do exist and that progress and investment in
this area are realistic aspirations as our level of understanding
improves.
Even within the research community, there are significant
debates about how much we need to understand about cell-
based treatment approaches before we progress to clinical
trials. These disagreements were very evident during a panel
session at the 2009 NHLBI Symposium on Cardiovascular
Regenerative Medicine, which science writer Anna Davison
captures in a Profile article (Davison, 2010). Nobody would
suggest that legitimate clinicians moving forward with trials are
doing so with anything less than good intentions or in any way
misrepresenting the situation to the patients involved. However,
that is unfortunately not always the case for companies that op-
erate outside standard jurisdiction (see Lau et al., 2008). It isprobably inevitable that an area surrounded by so much hype
and hope would become a focus for unethical behavior and, as
CBS’s 60 Minutes put it, ‘‘21st century snake oil’’ sales
approaches. Over recent months, the concern about companies
that are exploiting vulnerable patients has grown, with coverage
in the U.S. media and worldwide. In Ireland, for example, RTE´
News Prime Time recently presented an investigation of stem
cell tourism, and many organizations, including the ISSCR,
have issued warnings to patients thinking of embarking on costly
and potentially dangerous therapies to investigate the underlying
science carefully. There are resources already available to help
patients make such choices, but it is clear that there need to
be more. The ISSCR Task Force on Unproven Stem Cell Treat-
ments is set to issue its report soon, and the society will continue
to be active in providing scientifically supported advice about
stem cell-based treatment options. But, as Nature Medicine
pointed out recently, ensuring patient safety will most likely
require proactive regulatory oversight as well as information
and guidance (Editorial, 2010).
These topics, as well as, of course, a lot of exciting basic
science, will no doubt be at the forefront of discussions at the
upcoming ISSCR meeting. In keeping with the interest in prog-
ress toward translation, one of the satellite symposia before
the meeting is a timely workshop on best practices for clinical
trials. Other new additions include ‘‘Poster Teasers’’ and a young
investigators’ session on successful publication. I am sure you
will all join me in congratulating (in advance) the poster prize
winners, each of whom will receive a subscription to Cell Stem
Cell as part of their prize, and Joanna Wysocka for her
Outstanding Young Investigator award. If you want to know
more about Joanna’s research ahead of her presentation, check
out the article by Temple and colleagues in the ISSCR section of
this issue (Kokovay et al., 2010). Remember that whether or not
you are attending the meeting in person, you can follow the
proceedings and other stem cell events on Twitter using the
#ISSCR tag or by following us @cellstemcell. I look forward to
seeing you in San Francisco!REFERENCES
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